New Drug Approvals

AVORALSTAT March 23, 2016 - (0)

Avoralstat, BCX4161, CAS 918407-35-9 UNII: UX17773O15 513.5513, C28-H27-N5-O5 2-Pyridinecarboxylic acid, 3-(2-(((4-(aminoiminomethyl)phenyl)amino)carbonyl)-4-ethenyl-5-methoxyphenyl)-6-(((cyclopropylmethyl)amino)carbonyl)- 3-(2-((4-Carbamimidoylphenyl)carbamoyl)-4-ethenyl-5-methoxyphenyl)-6-((cyclopropylmethyl)carbamoyl)pyridine-2-carboxylic acid Hereditary angioedema (HAE) Kallikrein inhibitor BioCryst Pharmaceuticals BioCryst is also investigating second-generation plasma kallikrein inhibitors to avoralstat, for treating HAE (in February 2016, this program was listed as being in preclinical development). Prevent acute attacks in patients with hereditary angioedema (HAE); Treat hereditary angioedema (HAE) U.S. […]
BRIVARACETAM March 23, 2016 - (0)
PF-06747775 (Pfizer) Third generation covalent EGFR inhibitors March 23, 2016 - (0)
罗西替尼 роцилетиниб روسيليتينيب Rociletinib, CO-1686. Third generation covalent EGFR inhibitors March 23, 2016 - (0)
EGF 816 , Nazartinib March 23, 2016 - (0)

Mobile Site | Full Site